{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:16:35Z","timestamp":1791332195818,"version":"4.3.1"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of this questionnaire-based survey was to determine the \u2018acceptability\u2019 of Xaluprine\u00ae, a new oral liquid formulation of mercaptopurine, when administered chronically to children during the maintenance treatment phase of acute lymphoblastic leukaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This was a single centre survey of children (aged 3 to 16 years) and their parents at a routine follow-up visit during the maintenance phase of acute lymphoblastic leukaemica treatment. The questionnaire probed for their views on overall acceptability such as taste, smell, incidences of vomiting, ease and willingness to take Xaluprine\u00ae on a daily basis, and utilised a 5-point facial hedonic scale (1\u2009=\u2009bad, 5\u2009=\u2009good) as well as open\/closed questions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two children were recruited; 17 (77%) scored taste between 3 and 5 (\u2018okay\u2019 to \u2018good\u2019) and 20 (91%) scored smell between 3 and 5. Only four children (18%) reported an aftertaste. Of the five children (23%) who scored taste as 1 or 2 (\u2018bad\u2019), three found taking all oral medicines difficult. Six children (27%) reported vomiting, but this was not considered related to Xaluprine\u00ae. Seven children (32%) sometimes complained that they did not want to take Xaluprine\u00ae; 15 (68%) never complained. In response to the question, \u2018How easy is it for you to take Xaluprine\u00ae?\u2019 18 children (82%) reported that it was \u2018Easy all the time.\u2019 This was more favourable than other oral liquid medicines that they were taking concurrently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this survey show that Xaluprine\u00ae has good overall acceptability in the paediatric population and suggests that Xaluprine\u00ae is an important, alternative, age-appropriate formulation of mercaptopurine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155215577808","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T10:33:30Z","timestamp":1428057210000},"page":"387-395","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["\u2018Acceptability\u2019 of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia"],"prefix":"10.1177","volume":"22","author":[{"given":"Hussain","family":"Mulla","sequence":"first","affiliation":[{"name":"Nova Laboratories Limited, Leicester, UK"},{"name":"Department of Pharmacy, University Hospitals of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Buck","sequence":"additional","affiliation":[{"name":"St Albans, Herts, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Price","sequence":"additional","affiliation":[{"name":"Sir James Spence Institute, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Parry","sequence":"additional","affiliation":[{"name":"Sir James Spence Institute, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Bell","sequence":"additional","affiliation":[{"name":"Sir James Spence Institute, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Skinner","sequence":"additional","affiliation":[{"name":"Department of Paediatric and Adolescent Haematology and Oncology and Children's BMT Unit, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"key":"bibr1-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.257"},{"key":"bibr2-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1185\/146300907X167817"},{"key":"bibr3-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg031"},{"key":"bibr4-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1177\/000992280604500306"},{"key":"bibr5-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-300909"},{"key":"bibr6-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9924"},{"key":"bibr7-1078155215577808","unstructured":"Bhatia S, Landier W, Hageman L, et\u00a0al. Adherence to oral 6-mercaptopurine in African American and Asian children with acute lymphoblastic leukemia: a children's oncology group study.\n                      Blood.\n                      Epub ahead of print 12 July 2014."},{"key":"bibr8-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.03.057"},{"key":"bibr9-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.11.017"},{"key":"bibr10-1078155215577808","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831030-00002"},{"key":"bibr11-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665107005599"},{"key":"bibr12-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.S3.607"},{"key":"bibr13-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1185\/146300907X178941"},{"key":"bibr14-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"bibr15-1078155215577808","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200204060-00002"},{"key":"bibr16-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.154"},{"key":"bibr17-1078155215577808","unstructured":"European Medicines Agency: EMEA\/384641\/2006 - Assessment of the Paediatric Needs: Chemotherapy Products (Part I)."},{"key":"bibr18-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1582"},{"key":"bibr19-1078155215577808","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-8223(21)03656-7","volume":"85","author":"Lawless H","year":"1985","journal-title":"J Am Diet Assoc"},{"key":"bibr20-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0319-7"},{"key":"bibr21-1078155215577808","first-page":"412","volume-title":"Cancer nursing. Sudbury","author":"Camp-Sorrell D","year":"2005"},{"key":"bibr22-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-15"},{"key":"bibr23-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70600-9"},{"key":"bibr24-1078155215577808","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.04.069"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215577808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215577808","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215577808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:11Z","timestamp":1777688171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215577808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1177\/1078155215577808"],"URL":"https:\/\/doi.org\/10.1177\/1078155215577808","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,2]]}}}